Harpreet S. Takhar

Kaiser Permanente Southern California - Department of Research & Evaluation

Mission Viejo, CA

United States

SCHOLARLY PAPERS

2

DOWNLOADS
Rank 29,572

SSRN RANKINGS

Top 29,572

in Total Papers Downloads

2,201

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study

Number of pages: 27 Posted: 02 Sep 2021
Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Moderna, Inc. and Kaiser Permanente Southern California
Downloads 1,966 (10,540)

Abstract:

Loading...

COVID-19, SARS-CoV-2, mRNA-1273, vaccine effectiveness, variants, matched cohort

2.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. and Pfizer, Inc.
Downloads 235 (168,989)

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta